Spiro Medical, Inc., a newly established company developing the first Pulmonary Neuromodulation System for treating asthma, announced the successful closing of a $67 million Series A equity financing. The funding round included a syndicate of venture investors led by Andera Partners in Paris, Omega Funds in Geneva and Boston, and Sherpa Healthcare Partners in the Cayman Islands. Additional participants included HSG in Hong Kong, Supernova Invest in Paris, Northern Light Venture Capital in Menlo Park, and Hero Inc. Ltd in the UK, part of the India-based Hero Enterprise group.
Health Technology Insights: ZOLL Launches Fifth-Generation LifeVest WCD
Proceeds from the financing will support the development of a purpose-built Pulmonary Neuromodulation System and fund the clinical work needed to seek regulatory approval in the United States.
Raymond W. Cohen, chairman of the board, stated that the company is excited to work with leading venture capital investors who understand the potential of this novel technology. He explained that once available, the system could make a significant difference for patients living with asthma and other respiratory conditions.
Health Technology Insights: Datma and Rhythm Biosciences Partner on Genomic Data Collaboration
Spiro Medical also announced that Raphaël Wisniewski from Andera, Claudio Nessi from Omega, and Ouyang Xiangyu from Sherpa have joined its board of directors to help guide the company’s strategic growth.
Rinda Sama, CEO of Spiro Medical, said that the company is grateful to co-founder Stephen Pyles, M.D., for his vision and expects his continued contributions will be invaluable. She noted that the project benefits from existing patents and preliminary human data, which provide early insights into the potential of this neuromodulation approach. She added that the company is confident in its ability to build a world-class system thanks to the team’s extensive experience with implantable neuromodulation technologies.
Asthma is a common chronic lung disease affecting more than 28 million people in the United States and over 300 million worldwide. Many of its symptoms, including wheezing, shortness of breath, chest tightness, and coughing, are linked to altered nerve activation or regulation in the airways. Pulmonary neuromodulation targets these neural pathways to help manage these symptoms, offering a potentially transformative approach to treatment.
Health Technology Insights: OsteoCentric Technologies Appoints Matthew Collier to Board of Directors
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
